PC-3 Metastatic Tumor Model Service for Prostate Cancer

The PC-3 metastatic tumor model for prostate cancer is an androgen-independent xenograft system derived from a human bone metastasis, offering a faithful preclinical setting to study the dissemination of advanced, hormone-refractory prostate cancer. Alfa Cytology delivers complete PC-3 metastatic model services—from subcutaneous, orthotopic, and bone-directed engraftment to non-invasive imaging, treatment administration, and thorough endpoint analysis—giving your program dependable data on tumor growth, metastatic spread, and therapeutic response.

Overview of PC-3 Metastatic Tumor Model for Prostate Cancer

PC-3 was established in 1979 by Kaighn and colleagues from a grade IV prostatic adenocarcinoma that had metastasized to the lumbar vertebra of a 62-year-old Caucasian man. The line is androgen-independent: it does not express the androgen receptor or prostate-specific antigen (PSA), shows little response to androgens, glucocorticoids, or fibroblast growth factors, and is instead driven by epidermal growth factor receptor and TGF-α signaling together with PTEN loss. Cytogenetically, PC-3 cells are near-triploid (approximately 62 chromosomes) with no detectable Y chromosome, and ultrastructurally they display features of poorly differentiated adenocarcinoma of epithelial origin. These traits mirror the biology of castration-resistant prostate cancer (CRPC), making PC-3 the most frequently used model for late-stage, hormone-refractory disease.

Fig 1. The PC-3-Luc2/RGB spontaneous metastasis quantification workflow: subcutaneous injection at t=0, primary tumor growth and systemic spread (~3 weeks), resection at ~0.75 cm³ (~1 week), relapse to ~0.5 cm³ (t=2, ~3 weeks), followed by in vivo BLI, ex vivo BLI of hindlimb bone and lung, and three orthogonal quantification methods — BLI+ bone H&E/luciferase IHC, bone marrow cell Alu-qPCR, and lung serial-section H&E with luciferase IHC — enabling method-by-method sensitivity comparison for spontaneous PC-3 metastasis endpoints. (Haider, Marie-Therese, et al., 2024)

Among prostate cancer cell lines, PC-3 possesses the highest metastatic potential—surpassing DU145 and far exceeding LNCaP—and this behavior is recapitulated in vivo. Subcutaneous implantation in immunodeficient mice yields rapidly growing tumors suitable for pharmacology studies, whereas orthotopic implantation into the prostate gland more closely reproduces the organ context and natural metastatic routes. For dissemination work, intracardiac and tail vein injections model hematogenous spread, with PC-3 cells consistently establishing lymph node and bone metastases accompanied by osteolytic bone responses; direct intratibial inoculation is used to dissect tumor-bone microenvironment interactions. When engineered with luciferase or fluorescent reporters, PC-3 tumors and their metastases can be monitored longitudinally by in vivo imaging, while endpoint analysis—metastatic lesion enumeration, H&E histopathology, and immunohistochemistry—anchors quantitative readouts. Collectively, the PC-3 metastatic model is a workhorse for evaluating taxane-based chemotherapy, PI3K/AKT pathway inhibitors, anti-metastatic agents, and bone-targeted strategies in prostate cancer research.

Cell Line Information: PC-3

The table below details the key characteristics of PC-3 most relevant to metastatic prostate cancer studies.

Our Services

Our ServicesOur ServicesRecognized for deep expertise in prostate cancer modeling, Alfa Cytology offers customized PC-3 metastatic tumor model services covering the full preclinical pathway—cell authentication, reporter engineering, subcutaneous or orthotopic engraftment plus systemic and bone-directed dissemination formats, in vivo imaging, dosing, and comprehensive metastatic endpoint characterization. Each study is configured to answer your specific questions, whether on tumor progression, metastatic tropism, or therapeutic efficacy.

Workflow of PC-3 Metastatic Tumor Model Construction

Constructing a reliable PC-3 metastatic model involves coordinated quality control at the cellular level and disciplined execution in animals. The standard workflow is outlined below.

1. Cell line authentication and expansion: PC-3 cells are identity-verified by STR profiling, confirmed mycoplasma-negative, and expanded under standardized culture conditions to secure uniform viability and growth kinetics.
2. Reporter labeling (optional): For longitudinal tracking, cells are stably transduced with luciferase or fluorescent reporters and validated for signal intensity and stability prior to animal use.
3. Model format and route selection: The study design defines the platform—subcutaneous engraftment for pharmacology, orthotopic prostate implantation for organ-specific growth and spontaneous spread, tail vein or intracardiac injection for experimental metastasis, or intratibial inoculation for bone colonization—with matched immunodeficient hosts (nude, NOD/SCID, or NSG mice).
4. Mouse preparation and inoculation: Mice are acclimated, randomized, and implanted with PC-3 cells (commonly 1×10⁶ to 1×10⁷ cells, resuspended in PBS or medium with Matrigel depending on the route) under sterile, ethically approved surgical conditions.
5. Tumor and metastasis monitoring: Primary tumor volumes and body weight are measured on schedule, while metastatic burden is tracked by in vivo bioluminescence or fluorescence imaging in reporter-labeled studies, supplemented by scheduled health assessments.
6. Treatment administration: When tumors reach predefined size thresholds or imaging signals are established, animals are randomized to treatment and vehicle arms and dosed per the study plan with taxanes, PI3K/AKT inhibitors, anti-metastatic agents, or combinations.
7. Endpoint analysis: At study endpoint, prostate, draining lymph nodes, lungs, bones (including tibiae), and other organs are examined; metastatic lesions are counted, and tissues undergo H&E histopathology, immunohistochemistry, and molecular analyses as required.
8. Data analysis and reporting: Tumor growth curves, imaging time courses, metastasis counts, and survival data are analyzed statistically and compiled into a comprehensive report to inform candidate selection and mechanistic interpretation.

Fig 2. PC-3 Metastatic Tumor Model construction workflow.

Case Study-PC-3 Metastatic Tumor Model Development

Alfa Cytology has established PC-3 metastatic tumor models for a variety of preclinical prostate cancer programs. These platforms have supported the assessment of candidate compounds against primary tumor growth and metastatic dissemination, comparisons with reference treatment regimens, and investigations of bone-tumor interactions under controlled in vivo conditions. Case details and representative datasets are available to clients upon request, and model parameters can be adapted to the specific goals and endpoints of each study.

Why Choose Alfa Cytology?

Alfa Cytology pairs specialized prostate cancer modeling experience with rigorous, client-centered execution. Researchers select our PC-3 metastatic model service for the following reasons:

• Established proficiency with androgen-independent prostate cancer models and their metastatic behavior in vivo.
• Versatile engraftment formats spanning subcutaneous, orthotopic, tail vein, intracardiac, and intratibial routes.
• Non-invasive in vivo imaging capability through stable luciferase or fluorescent reporter labeling.
• Uncompromising cell line authentication and mycoplasma screening at every project stage.
• Tailored treatment arms, survival endpoints, and bone-focused histopathology matched to each compound.
• Proactive communication and punctual delivery of organized, decision-ready reports.

Contact Us

If your prostate cancer program requires a metastatic model with proven bone and lymph node tropism, we are ready to assist. Contact us to discuss how the PC-3 metastatic tumor model can be configured for your study, and reach out today to let Alfa Cytology generate the preclinical evidence your project needs.

For research use only. Not intended for any clinical use.